IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants

Cytokine and Growth Factor Reviews

Volumn 25, Issue 4, 2014, Pages 437-442

  Ranasinghe, Charani ^a   Trivedi, Shubhanshi ^a   Wijesundara, Danushka K ^a,b   Jackson, Ronald J ^a  

^a Australian National University   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

CD8 T cell avidity; IL 13Ra2; IL 4R antagonist; Infection and immunity; Vaccines

Indexed keywords

DUPILUMAB; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR TYPE I; INTERLEUKIN 4 RECEPTOR TYPE II; IL4 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 13; INTERLEUKIN 4;

ANTIGEN SPECIFICITY; ASTHMA; ATOPIC DERMATITIS; BIOLOGICAL FUNCTIONS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHLAMYDIASIS; CHRONIC GRAFT REJECTION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; MACROPHAGE; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; VACCINATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTAGONISTS AND INHIBITORS; HYPERSENSITIVITY; IMMUNOLOGY; NEOPLASM; TH1 CELL; TH2 CELL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTERLEUKIN-4; NEOPLASMS; RECEPTORS, INTERLEUKIN-4; TH1 CELLS; TH2 CELLS;

EID: 84907965970     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.07.010     Document Type: Short Survey

References (89)

1. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat Rev Immunol 2010, 10:225-235.
2. Jiang S., Dong C. A complex issue on CD4(+) T-cell subsets. Immunol Rev 2013, 252:5-11.
3. Mohrs M., Ledermann B., Kohler G., Dorfmuller A., Gessner A., Brombacher F. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 1999, 162:7302-7308.
4. Hurdayal R., Brombacher F. The role of IL-4 and IL-13 in cutaneous Leishmaniasis. Immunol Lett 2014, 8. 00004-2.
5. Maizels R.M., Hewitson J.P., Smith K.A. Susceptibility and immunity to helminth parasites. Curr Opin Immunol 2012, 24:459-466.
6. Howell M.D., Gallo R.L., Boguniewicz M., Jones J.F., Wong C., Streib J.E., et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006, 24:341-348.
7. Sivaprasad U., Warrier M.R., Gibson A.M., Chen W., Tabata Y., Bass S.A., et al. IL-13Ralpha2 has a protective role in a mouse model of cutaneous inflammation. J Immunol 2010, 185:6802-6808.
8. He R., Kim H.Y., Yoon J., Oyoshi M.K., MacGinnitie A., Goya S., et al. Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13. J Allergy Clin Immunol 2009, 124:761-770. e1.
9. Licona-Limon P., Kim L.K., Palm N.W., Flavell R.A. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013, 14:536-542.
10. Halim T.Y., Steer C.A., Matha L., Gold M.J., Martinez-Gonzalez I., McNagny K.M., et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity 2014, 40:425-435.
11. + Th2 cell responses. J Immunol 2014, 192:2442-2448.
12. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009, 9:91-105.
13. Tabata Y., Khurana Hershey G.K. IL-13 receptor isoforms: breaking through the complexity. Curr Allergy Asthma Rep 2007, 7:338-345.
14. Liang H.E., Reinhardt R.L., Bando J.K., Sullivan B.M., Ho I.C., Locksley R.M. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol 2012, 13:58-66.
15. Lee Y.J., Holzapfel K.L., Zhu J., Jameson S.C., Hogquist K.A. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol 2013, 14:1146-1154.
16. Walker J.A., Barlow J.L., McKenzie A.N. Innate lymphoid cells - how did we miss them?. Nat Rev Immunol 2013, 13:75-87.
17. Chen W., Sivaprasad U., Tabata Y., Gibson A.M., Stier M.T., Finkelman F.D., et al. IL-13Ralpha2 membrane and soluble isoforms differ in humans and mice. J Immunol 2009, 183:7870-7876.
18. Heller N.M., Qi X., Junttila I.S., Shirey K.A., Vogel S.N., Paul W.E., et al. Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal 2008, 1:ra17.
19. LaPorte S.L., Juo Z.S., Vaclavikova J., Colf L.A., Qi X., Heller N.M., et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 2008, 132:259-272.
20. Andrews A.L., Holloway J.W., Holgate S.T., Davies D.E. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J Immunol 2006, 176:7456-7461.
21. Andrews A.L., Nordgren I.K., Campbell-Harding G., Holloway J.W., Holgate S.T., Davies D.E., et al. The association of the cytoplasmic domains of interleukin 4 receptor alpha and interleukin 13 receptor alpha 2 regulates interleukin 4 signaling. Mol Biosyst 2013, 9:3009-3014.
22. McKenzie A.N., Fallon P.G. Decoy receptors in the regulation of T helper cell type 2 responses. J Exp Med 2003, 197:675-679.
23. Kasaian M.T., Raible D., Marquette K., Cook T.A., Zhou S., Tan X.Y., et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 2011, 187:561-569.
24. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12:99-106. [Epub 2005 Dec 4].
25. Zhao Z., Wang L., Xu W. IL-13Ralpha2 mediates PNR-induced migration and metastasis in ERalpha-negative breast cancer. Oncogene 2014, 21:53.
26. Fujisawa T., Joshi B.H., Puri R.K. IL-13 regulates cancer invasion and metastasis through IL-13Ralpha2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012, 131:344-356.
27. Fujisawa T., Joshi B.H., Puri R.K. Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer. J Transl Med 2011, 9:37.
28. Nakashima H., Terabe M., Berzofsky J.A., Husain S.R., Puri R.K. A novel combination immunotherapy for cancer by IL-13Ralpha2-targeted DNA vaccine and immunotoxin in murine tumor models. J Immunol 2011, 187:4935-4946.
29. Nakashima H., Husain S.R., Puri R.K. IL-13 receptor-directed cancer vaccines and immunotherapy. Immunotherapy 2012, 4:443-451.
30. Fichtner-Feigl S., Strober W., Geissler E.K., Schlitt H.J. Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol 2008, 1(Suppl. 1):S24-S27.
31. Brunner S.M., Schiechl G., Kesselring R., Martin M., Balam S., Schlitt H.J., et al. IL-13 signaling via IL-13Ralpha2 triggers TGF-beta1-dependent allograft fibrosis. Transpl Res 2013, 2:16.
32. Starkey M.R., Essilfie A.T., Horvat J.C., Kim R.Y., Nguyen D.H., Beagley K.W., et al. Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease. Mucosal Immunol 2013, 6:569-579.
33. Campbell-Harding G., Sawkins H., Bedke N., Holgate S.T., Davies D.E., Andrews A.L. The innate antiviral response upregulates IL-13 receptor alpha2 in bronchial fibroblasts. J Allergy Clin Immunol 2013, 131:849-855.
34. + T cell can give rise to progeny expressing type 1 and/or type 2 cytokine genes and can retain its multipotentiality through many cell divisions. Proc Natl Acad Sci U S A 1997, 94:8070-8075.
35. + T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007, 178:2370-2379.
36. Kienzle N., Baz A., Kelso A. Profiling the CD8 low phenotype, an alternative career choice for CD8 T cells during primary differentiation. Immunol Cell Biol 2004, 82:75-83.
37. + T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med 1994, 180:489-495.
38. Imrie A., Meeks J., Gurary A., Sukhbataar M., Kitsutani P., Effler P., et al. Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 2007, 81:10081-10091.
39. Jackson R.J., Ramsay A.J., Christensen C.D., Beaton S., Hall D.F., Ramshaw I.A. Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001, 75:1205-1210.
40. + T cells correlates with higher quality anti-viral immunity. PLOS ONE 2013, 8:e55788.
41. Ahlers J.D., Belyakov I.M., Terabe M., Koka R., Donaldson D.D., Thomas E.K., et al. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L. Proc Natl Acad Sci U S A 2002, 99:13020-13025.
42. + T cell responses: correlation of cytokine profile and TCR avidity. J Immunol 2004, 172:5553-5560.
43. Ranasinghe C., Ramshaw I.A. Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity. Eur J Immunol 2009, 39:1819-1830.
44. Ranasinghe C., Trivedi S., Stambas J., Jackson R.J. Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity. Mucosal Immunol 2013, 6:1068-1080.
45. Jackson R.J., Boyle D.B., Ranasinghe C. Heterologous prime-boost regimens in DNA vaccination. DNA vaccines methods in molecular biology 2014, Springer. M. Rinaldi, D. Fioretti, S. Iurescia (Eds.).
46. Hemachandra A., Puls R.L., Sirivichayakul S., Kerr S., Thantiworasit P., Ubolyam S., et al. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. Hum Vaccin 2010, 6:835-840.
47. Kelleher A.D., Puls R.L., Bebbington M., Boyle D., Ffrench R., Kent S.J., et al. A randomised, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006, 20:294-297.
48. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220. [Epub 009 Oct 20].
49. Lightwood D., O'Dowd V., Carrington B., Veverka V., Carr M.D., Tservistas M., et al. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol 2013, 425:577-593.
50. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
51. Wechsler M.E. Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. N Engl J Med 2013, 368:2511-2513.
52. Tomkinson A., Duez C., Cieslewicz G., Pratt J.C., Joetham A., Shanafelt M.C., et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001, 166:5792-5800.
53. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., et al. Interleukin-13: central mediator of allergic asthma. Science 1998, 282:2258-2261.
54. Finkelman F.D., Katona I.M., Urban J.F., Holmes J., Ohara J., Tung A.S., et al. IL-4 is required to generate and sustain invivo IgE responses. J Immunol 1988, 141:2335-2341.
55. Finkelman F.D., Yang M., Perkins C., Schleifer K., Sproles A., Santeliz J., et al. Suppressive effect of IL-4 on IL-13-induced genes in mouse lung. J Immunol 2005, 174:4630-4638.
56. Cohn L., Homer R.J., Marinov A., Rankin J., Bottomly K. Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 1997, 186:1737-1747.
57. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep 2013, 13:415-420.
58. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Curr Allergy Asthma Rep 2004, 4:123-131.
59. Voehringer D., Reese T.A., Huang X.Z., Shinkai K., Locksley R.M. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. J Exp Med 2006, 203:1435-1446.
60. Kim S., Prout M., Ramshaw H., Lopez A.F., LeGros G., Min B. Cutting edge: basophils are transiently recruited into the draining lymph nodes during helminth infection via IL-3, but infection-induced Th2 immunity can develop without basophil lymph node recruitment or IL-3. J Immunol 2010, 184:1143-1147.
61. Cohn L., Elias J.A., Chupp G.L. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004, 22:789-815.
62. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-149.
63. Halim T.Y.F., Krauss R.H., Sun A.C., Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012, 36:451-463.
64. Schmitz J., Owyang A., Oldham E., Song Y.L., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
65. Yu X., Pappu R., Ramirez-Carrozzi V., Ota N., Caplazi P., Zhang J., et al. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol 2014, 7:730-740.
66. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292.
67. Van Dyken S.J., Locksley R.M. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol 2013, 31:317-343.
68. Cook P.C., Jones L.H., Jenkins S.J., Wynn T.A., Allen J.E., MacDonald A.S. Alternatively activated dendritic cells regulate CD4(+) T-cell polarization in vitro and in vivo. Proc Natl Acad Sci U S A 2012, 109:9977-9982.
69. Guilliams M., Lambrecht B.N., Hammad H. Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Mucosal Immunol 2013, 6:464-473.
70. Ballesteros-Tato A., Leon B., Lund F.E., Randall T.D. Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat Immunol 2010, 11:216-224.
71. Iijima N., Mattei L.M., Iwasaki A. Recruited inflammatory monocytes stimulate antiviral Th1 immunity in infected tissue. Proc Natl Acad Sci U S A 2011, 108:284-289.
72. Lambrecht B.N., Hammad H. Lung dendritic cells in respiratory viral infection and asthma: from protection to immunopathology. Annu Rev Immunol 2012, 30:243-270.
73. Plantinga M., Guilliams M., Vanheerswynghels M., Deswarte K., Branco-Madeira F., Toussaint W., et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen. Immunity 2013, 38:322-335.
74. Landsman L., Jung S. Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages. J Immunol 2007, 179:3488-3494.
75. + T cells. Proc Natl Acad Sci U S A 2008, 105:17475-17480.
76. Wijesundara D.K., Jackson R.J., Tscharke D.C., Ranasinghe C. IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8(+) T cell avidity following HIV-1 recombinant pox viral vaccination. Vaccine 2013, 31:4548-4555.
77. Harland K.L., Day E.B., Apte S.H., Russ B.E., Doherty P.C., Turner S.J., et al. Epigenetic plasticity of Cd8a locus during CD8(+) T-cell development and effector differentiation and reprogramming. Nat Commun 2014, 5:3547.
78. Van Dyken S.J., Mohapatra A., Nussbaum J.C., Molofsky A.B., Thornton E.E., Ziegler S.F., et al. Chitin activates parallel immune modules that direct distinct inflammatory responses via innate lymphoid type 2 and gammadelta T cells. Immunity 2014, 40:414-424.
79. Kim M., Lim S.J., Oidovsambuu S., Nho C.W. Gnetin H isolated from Paeonia anomala inhibits FcepsilonRI-mediated mast cell signaling and degranulation. J Ethnopharmacol 2014, 14:356-360.
80. Kim Y.H., Park C.S., Lim D.H., Ahn S.H., Son B.K., Kim J.H., et al. Beneficial effect of anti-interleukin-33 on the murine model of allergic inflammation of the lower airway. J Asthma 2012, 49:738-743.
81. Bando J.K., Nussbaum J.C., Liang H.E., Locksley R.M. Type 2 innate lymphoid cells constitutively express arginase-I in the naive and inflamed lung. J Leukoc Biol 2013, 94:877-884.
82. Roediger B., Kyle R., Yip K.H., Sumaria N., Guy T.V., Kim B.S., et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 2013, 14:564-573.
83. Kaiko G.E., Foster P.S. New insights into the generation of Th2 immunity and potential therapeutic targets for the treatment of asthma. Curr Opin Allergy Clin Immunol 2011, 11:39-45.
84. Caubet J.C., Masilamani M., Rivers N.A., Mayer L., Sampson H.A. Potential non-T cells source of interleukin-4 in food allergy. Pediatr Allergy Immunol 2014, 25:243-249.
85. Motomura Y., Morita H., Moro K., Nakae S., Artis D., Endo T.A., et al. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 2014, 40:758-771.
86. Ohnmacht C., Schwartz C., Panzer M., Schiedewitz I., Naumann R., Voehringer D. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity 2010, 33:364-374.
87. Vijayanand P., Seumois G., Simpson L.J., Abdul-Wajid S., Baumjohann D., Panduro M., et al. Interleukin-4 production by follicular helper T cells requires the conserved Il4 enhancer hypersensitivity site V. Immunity 2012, 36:175-187.
88. Harada Y., Tanaka S., Motomura Y., Harada Y., Ohno S., Ohno S., et al. The 3' enhancer CNS2 is a critical regulator of interleukin-4-mediated humoral immunity in follicular helper T cells. Immunity 2012, 36:188-200.
89. + T and B cell immunity with greater protective efficacy. Vaccine 2014, [accepted].